OmegAD (Omega-3 and Alzheimer's Disease)

This study has been completed.
Sponsor:
Information provided by:
Karolinska University Hospital
ClinicalTrials.gov Identifier:
NCT00211159
First received: September 13, 2005
Last updated: February 7, 2007
Last verified: April 2005
  Purpose

Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients


Condition Intervention
Alzheimer's Disease
Drug: EPAX 1050TG

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-Blind Trial

Resource links provided by NLM:


Further study details as provided by Karolinska University Hospital:

Primary Outcome Measures:
  • Cognition measured according to ADAS-cog, MMSE scales

Secondary Outcome Measures:
  • Safety, tolerability, blood pressure

Estimated Enrollment: 204
Study Start Date: December 2000
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Alzheimer's disease with MMSE 15-30, living in own homes, treated with stable dose of acetylcholine esterase inhibitor for >3 months and remaining on that treatment for the study period

Exclusion Criteria: Already treated with omega-3 fatty acids, NSAIDs, warfarin, being an alcohol abuser, suffering from serious concomitant disease or not having a caregiver

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00211159

Locations
Sweden
Karolinska University Hospital Huddinge
Stockholm, Sweden, S-141 86
Sponsors and Collaborators
Karolinska University Hospital
Investigators
Principal Investigator: Tommy Cederholm, MD, PhD Karolinska University Hospital
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00211159     History of Changes
Other Study ID Numbers: OmegAD#1
Study First Received: September 13, 2005
Last Updated: February 7, 2007
Health Authority: Sweden: Swedish National Council on Medical Ethics

Keywords provided by Karolinska University Hospital:
Alzheimer's disease
Omega-3 fatty acid
Dietary supplementation
Cognition
Safety

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on April 17, 2014